The matrix metalloproteinases are a family of nearly 30 enzymes that are intimately involved in tissue remodeling. Disease processes associated with the matrix metalloproteinases are generally related to imbalance between the inhibition and activation of matrix metalloproteinases resulting in excessive degradation of the extracellullar matrix. These include osteoarthritis, rheumatoid arthritis, tumor metastasis and congestive heart failure. Despite massive research and development efforts, there are only two drugs launched on the market: periostat (doxycycline), a tetracycline used for periodontal disease and glucosemine sulfate, for osteoarthritis. Possible reasons for the low success rate of matrix metalloproteinase inhibitors in the clinic are mainly from unwanted side effects caused by their lack of selectivity, since inhibition of collagenase-1 may be responsible for the musculoskeletal side effects observed clinically with broad-spectrum inhibitors. Considering these data, many efforts were directed to developing a more selective second generation of inhibitors against the specific matrix metalloproteinases believed to be involved in the different pathologies. This review mainly focuses on selective matrix metalloproteinase inhibitors development on matrix metalloproteinases in terms of antitumor since the late 90s, in terms of synthetic compounds of low molecular mass incorporating specific zinc-binding groups, natural products and their derivatives. Through these methods, new hope is emerging in the form of synthetic and natural matrix metalloproteinase inhibitors for the prevention and treatment of cancer.
INTRODUCTION

History of Matrix Metalloproteises
Matrix metalloproteinases (MMPs) are a family of enzymes capable of degrading the constituents of the extracellular matrix (ECM) and the basement-membrane including components such as aggrecan, collagen, elastin, fibronectin, gelatin, and laminin. MMPs are essential for several processes that are part of normal physiological development including growth, wound healing, and other functions requiring tissue reorganization [1] [2] [3] . MMPs are secreted by a variety of connective tissue and pro-inflammatory cells including fibroblasts, osteoblasts, endothelial cells, macrophages, neutrophils and lymphocytes. Most are expressed as inactive zymogens, which are subsequently processed by other proteolytic enzymes (serine proteases, furin, plasmin and others) to generate the active forms. Under normal physiological conditions, the proteolytic activity of the MMPs is controlled at any of the following three known stages: transcription, activation of the zymogens and inhibition of the active forms by various tissue inhibitors of matrix metalloproteinases (TIMPs). In pathological conditions this equilibrium is shifted towards increased MMP activity leading to tissue degradation.
One of the earliest descriptions of MMPs in 1949 was as depolymerising enzymes [4] which, it was proposed, could facilitate tumor growth by making connective tissue stroma, including that of small blood vessels, more fluid. Some 13 years later, one of the earliest descriptions of MMP activity *Address correspondence to these authors at the Jiangsu Key Laboratory for TCM Formulae Research, Nanjing University of Chinese Medicine, 138 Xianlin Road, 210046, Nanjing, Jiangsu, P.R. China; Tel/Fax: +86-25-85811916; E-mail: yupingtang@njutcm.edu.cn; dja@njutcm.edu.cn in animals was found in the collagenolytic properties of tadpole tissues [5] . During the next 20 years, several mammalian enzymes were partially purified but it was not until 1985 that the field really developed when structural homologies became apparent, allowing many new members to be identified through the techniques of molecular biology [6] .
Nowadays twenty-eight members of the MMP family have been isolated and characterized, and they may be subdivided into six classes according to their substrate specificity, primary structures and their cellular localization. Table 1 reports the structural features used to classify these enzymes in their subfamilies.
Structure of MMPs
MMPs contain the same basic structural features despite the observed variability in substrate specificity (Fig. 1) . MMPs are synthesized as inactive zymogens and secreted prior to activation, this 'pre-proMMP' [3] contains an Nterminal signal pre-domain region that directs the protein for secretion, after which, the enzyme exists as the inactive 'proMMP'. The propeptide domain consists of approximately 80 amino acids containing a conserved cysteine in the sequence -PRCGXPD-that suppresses enzyme activity by coordination of a cysteinyl sulfur atom (shown in bold) to the active site zinc (II) ion. The enzyme becomes active upon cleavage of the propeptide domain by other MMPs or proteases such as plasmin in what is termed the 'cysteine switch' mechanism [3] .
Mechanism of MMPs
The 170 amino acid catalytic domain is composed of a five-stranded-sheet, three-helices, and bridging loop structures [3] . The active site contains two zinc (II) ions, one MMP-1 Collagenase 1 [7] MMP-8 Collagenase 2 [8] MMP-13 Collagenase 3 [9] Collagenases MMP-18 Collagenase 4 [10] MMP-2 Gelatinases A [7] Gelatinases MMP-9 Gelatinases B [11] MMP-3 Stromelysin 1 [7] MMP-10 MMP-24 MT5-MMP [18] (B) GPI-anchored MMP-17 MT4-MMP [19] Membrane-Type MMPs (MT-MMPs)
MMP-25 MT6-MMP [20] MMP-4 ND [21] MMP-5 Marinobacter MicroPeroxidase-5 [22] MMP-6 cartilage acid metalloproteinase [23] MMP-12 Macrophage elastase [24] MMP-19 ND [25] MMP-20 Enamelysin [26] MMP-21 ND [27] MMP-22 ND [28] MMP-23 CA-MMP [29] MMP-27 ND [30] Other MMPs MMP-28 Epilysin [31] Note: ND = not defined; CA-MMP: Cysteine array matrix metalloproteinase. serves a structural role and the other is the peptide hydrolysis site. Buried in the protein, the structural zinc (II) ion is bound by one aspartate and three histidine residues in a tetrahedral geometry. The catalytic zinc is coordinated by three histidine nitrogen atoms (shown in bold) in a conserved sequence -VAAHEXGHXXGXXH- [32] . In the resting state, water molecules occupy the remainder of the coordination sphere and are critical for peptide hydrolysis [33] . Upon binding of a carbonyl oxygen of a peptide to the zinc (II) ion, the amide bond is attacked by a zinc-bound water molecule that is hydrogen bonded to an adjacent glutamate residue. Proton transfer from the water molecule to the glutamate residue and then to the amide nitrogen completes the cleavage of the peptide (Fig. 2 ).
Role of MMPs in Cancer
The ability of MMPs to degrade components of the extracellular matrix is essential to tasks such as cell growth, cell division, bone growth, wound healing, embryogenesis, and angiogenesis [1] . In this review, we only focus on the role of MMPs in cancer.
Tumor-associated MMP expression and activity is the result not only of tumor cell-expression of MMPs, but including a robust contribution of surrounding stromal cells. In fact, in epithelial cancers most of the up-regulated MMPs are expressed by the host stromal cells [34] . The high level of MMPs at the tumor-stroma interface is indicative of stromal cell up-regulation of MMP expression by supporting stromal cells in areas of active invasion [35] . Multiple MMPs are induced in connective tissue cells, such as fibroblasts and inflammatory cells responding to a tumor, hence MMPs from adjacent stromal cells provoke invasion by the malignant epithelial cells [36] . MMP expression is generally present in higher amounts in and around malignant cancers compared to normal, benign, or pre-malignant tissues. The two MMPs most closely correlated with metastatic potential are the 72 kDa MMP-2 and the 92 kDa MMP-9. Both degrade denatured collagens and type IV collagen present in the basement membrane and are therefore designated type IV collagenases/gelatinases [37] . Metastatic tumor cell lines express higher levels of gelatinases than nonmetastatic counterparts [38] . Gelatinases are also produced by nonmalignant cells present in a tumor, such as mesenchymal cells [39, 40] and tumor-infiltrating macrophages [41, 42] . Gelatinases produced by endothelial cells play a role in angiogenesis [43] [44] [45] . The growth of a solid tumor is largely dependent on nutrients provided by the vasculature recruited by the tumor through angiogenesis. The formation of new capillaries by endothelial cells requires migration of endothelial cells and extensive remodeling of the tissue, a process that requires gelatinases and other proteinases. In addition, there is emerging evidence for a protective role of some MMPs in tumor progression [46] . These data support the notion that MMPs can contribute to virtually all stages of cancer from initiation through progression and metastasis to the establishment of metastatic disease at distal sites and thereby provide ideal targets for the molecular imaging of cancer.
MT-MMPs are a unique subset tethered to the cell membrane by a transmembrane domain or glycosylphosphatidylinositol (GPI) anchor [47] . The first identified MT1-MMP (MMP- 14) , has been shown to play a central role in tumorcell invasion and migration [48] . It hydrolyses constituents of the ECM directly [49] [50] [51] and activates proMMP-2 efficiently, activated MMP-2 cleaves the basement membrane type IV collagen [52] [53] [54] [55] . Because MMP-14 is highly localized at the leading edge of invading cancer cells and is a powerful proteolytic enzyme, it may be a good target for inhibition of tumor [56] .
Early Strategies for MMP Inhibition
Due to the variety of diseases that MMPs are correlated with (vide supra), the inhibition of MMPs has grown into an important field for the development of potential chemotherapeutics. Most matrix metalloproteinase inhibitors (MMPIs) use the same basic design strategy ( Fig. 3) : a peptidomimetic backbone coupled with a metal chelating moiety (often referred to as a zinc-binding group or ZBG) [6] . Following a substrate-based approach, early MMPIs were designed to mimic natural substrates of MMPs by using a short peptide derivative attached to a ZBG. Since these early efforts, MMPI design has become more structure-based, due to the abundance of NMR and X-ray structural data available for MMPs [57] . Fig. (3) . Generalized structure for MMPIs. The ZBG binds to the catalytic zinc (II) ion. The 'P ' substitutents occupy various subsite pockets in the MMP active site.
An alternative to small molecule therapeutic strategies for MMP inhibition has been the use of the naturally occurring TIMPs [58] . TIMPs are a family of at least four known 20-29 kDa proteins (TIMP-1, TIMP-2, TIMP-3, and TIMP-4) that inhibit MMP activity. This inhibition is due to the reversible formation of a heterodimeric assembly between a TIMP and a MMP. TIMPs inhibit MMPs by binding of the active site zinc (II) ion (much like synthetic inhibitors) by using residue Cys1; the X-ray crystal structures of TIMP-1 bound to MMP-3 and TIMP-2 bound to MMP-14 have been determined [59] . The sulfur atom of the cysteine residue is not coordinated, as it is involved in a disulfide bond with Cys70. However, the disulfide bond provides a rigid Nterminus that positions the-amino nitrogen atom and carbonyl oxygen atom in a geometry that facilitates zinc binding. However, this protein-based inhibition strategy has strict limitations due to the inadequate pharmacological stability of TIMPs [58] . Also, TIMPs can inhibit other metalloproteins including ADAMs (a disintegrin and metalloproteinase) and ADAMTs (ADAMs with thrombospondin motifs) [60] . Furthermore, studies have found that TIMPs are too large to penetrate cartilage, which may limit their medical usefulness [61] .
Significance of the Active Site 'Subsites' in Inhibitor Design
NMR and X-ray crystal structures have yielded valuable information on the zinc (II) ion active site of MMPs [62] . The active site can be described as several substrate interaction sites termed 'subsites'. The diversity in substrate selectivity between different MMPs is attributed to the variety of residues found in these subsites [6] . Using (Fig. 4) as a reference, the subsites to the 'left' of the zinc (II) ion are classified as 'unprimed' (e.g. S1, S2, S3), while the subsites to the 'right' of the zinc (II) ion are classified as the 'primed' subsites (e.g. S1', S2', S3'). The functional groups of MMPIs that are designed to interact with specific subsites (Fig. 3) are termed 'P' or 'P'' groups, that is, a P1 group is expected to interact with the S1 subsite.
Most efforts in MMPI design have focused on the primed subsites (termed 'right-handed' inhibitors), particularly the S1 pocket. Selectivity could potentially be achieved by taking advantage of differences in size of the S1 pocket among the various MMPs. Selective inhibition of MMPs is possible due to differences in the depth of the S1 pocket. From X-ray crystallographic and NMR analysis and homology modeling, the MMPs may be classified into two broad structural classes, those with a relatively deep S1 pocket (MMP-2, 3, 8, 9, and 13) and those with a shallow S1 pocket (MMP-1 and 7) [63, 64] . Consequently, incorporation of an extended P1 group (e.g. biphenyl) leads to selective inhibition, whereas the presence of smaller P1 groups generally leads to broad spectrum inhibition. The effect of the P1 substituent is shown in examples 1a and 1b (Fig. 5) . Modest 700-fold selectivity for inhibition of MMP-2 over MMP-1 was obtained for 1b [65] .
The solvent exposed S2' pocket is located directly above the opening to the S1' pocket. The S2' cavity is hydrophobic in MMPs with the exception of MMP-1 and MMP-7 where it contains Ser and Thr residues, respectively. The S2' subsite does offer opportunities for selectivity, but has taken a secondary role behind the S1' pocket. A class of inhibitors designed with bulky hydrophobic P2' substituents takes advantage of the differences in the S2' subsites and exhibits selectivity for MMP-2, MMP-3, MMP-8, MMP-9, and MMP-13 over MMP-1 and MMP-7 [66] . Other MMPIs have incorporated bulky P2' groups to improve the pharmacokinetic properties of MMPIs by shielding amide bonds of the inhibitor from hydrolysis [67] .
The S3' subsite is a solvent exposed region that constitutes the outer rim of the S1' pocket entrance. This subsite has also taken a lesser role in the design of MMPIs. Nevertheless, a recent study has shown specificity can be obtained by some P3' substituents. For example, to enhance selectivity of MMP-3 over MMP-2, inhibitors incorporating-substituted benzylic groups at the P3' position resulted in a 1000-fold decrease in potency against MMP-2, while having little affect on the activity against MMP-3 [68] .
The unprimed subsites are more loosely defined and historically have been considered less attractive as targets for selective inhibitor design than the primed subsites. The unprimed region can be described as a more solvent exposed region with less segregation between subsites when compared with the primed subsites. The S2 subsite occupies a region adjacent to the zinc (II) ion, while the S1 and S3 subsites are located further away from the catalytic center. Recent substrate and inhibitor studies have demonstrated the importance of the unprimed subsites. For example, the substrate selectivity between MMP-2 and MMP-9 is partially attributed to the differences in the S2 subsite residues where MMP-2 contains a Glu and MMP-9 contains an Asp in the analogous position. Modeling studies have shown the Glu residue can hydrogenate bond with specific substrates while the Asp cannot form these interactions due to the shorter side chain length [69] . Nevertheless, early 'left-handed' MMPIs showed poor inhibitory activity, which reduced research efforts on the unprimed side of the active site. Although generally less popular, there have been encouraging results demonstrating selectivity can be obtained through left-handed inhibitors [70, 71] . The S1 and S3 subsites have been shown to play a useful role in devising inhibitors for targeting certain MMPs over MMP-1 [71] . For example, thiadiazolebased inhibitors [71] that target the unprimed subsites demonstrate selective inhibition of MMP-3 (Ki = 0.018 M) over MMP-1 (no inhibition).
MMPIs have been designed that exploit both the unprimed and primed subsites. A recent example of this type of MMPIs has yielded potent inhibitors of MMP-13 with selectivity over MMP-1. Substituents designed to interact with the deep S1' pocket of MMP-13 in combination with moieties selected to interact with the S2 subsite produced a greater 100-fold selectivity for MMP-13 over MMP-1 [72] . Clearly the active site subsites have provided a variety of opportunities to design selective inhibitors.
MMP INHIBITORS
Two generations of synthetic MMPIs have been developed in this long period but, currently, there are only two drugs launched on the market: Periostat (doxycycline), a tetracycline used for periodontal disease and glucosemine sulfate, for osteoarthritis.
In the past few years, some potent 'broad spectrum' MMPIs have been proposed and tested against tumors [73] . Some of them have entered clinical trials, but at present none of them is on the market. Compounds such as, CGS-27023A 2 and Prinomastat (AG-3340) 3 (Fig. 6) have shown a severe musculoskeletal syndrome, with fibroproliferative effects in the joint capsule of the knees [74] [75] [76] . These effects are thought to be linked to an impairment of normal tissue remodelling governed by the MMP-1 and/or by sheddases such as TNF-convertase [77] . For these reasons, a lack of activity with respect to MMP-1 is considered to be an important factor in reducing some of the side effects found for 'nonselective' MMPI such as AG-3340, 3 [78] .
Considering these data, many efforts were directed to develop a more selective second generation of inhibitors against the specific MMPs believed to be involved in the different pathologies since the late 90s. In this review, we only focus on selective MMPIs in antitumor since the late 90s. The MMPIs discussed will be categorized according to the nature of group used to bind the active site metal ion. Based on this premise, MMPIs can be broadly categorized into eight groups: hydroxamic acids, retrohydroxamic acids, carboxylic acids, phosphorus, thiols, thiirane, other ligands, and natural products.
Hydroxamic Acid-Based MMPIs
The hydroxamic acid group is overwhelmingly the most commonly used ZBG in inhibitor design and is generally found to be the most effective. Hydroxamic acid bind the catalytic zinc (II) ion in a bidentate fashion, blocking substrate access to the active site and rendering the metal incapable of peptide hydrolysis. With the advent of structurebased design, MMPIs have been further modified in an effort to obtain greater specificity and potency.
A set of representative examples of selective hydroxamic acid-based MMPIs are shown in (Table 2) .
Hanessian et al. undertook a comparative study of fully automated docking programs for reported X-ray and NMR structures of MMP/inhibitor complexes, revealing AutoDock to be reliable and efficient in predicting binding modes observed in the X-ray co-crystals of these inhibitors [79] . Based on the results, they designed and synthesized a series of N-arylsulfonyl S-alkyl homocysteine hydroxamic acids (4) ( Table 2 ) with low nanomolar and subnanomolar inhibitory activity toward various MMPs [80, 81] . The variations at the P1, P1 and P2 sites revealed a remarkable effect on the potency and selectivity of these compounds against a variety of MMPs. Compound (4-1) shown in Table 2 against MMP-9 with selectivity versus MMP-1 of 2900 times.
Barta et al. reported a series of novel, MMP-1 sparing arylhydroxamic acid sulfonamides (5) ( Table 2 ) with activity against MMP-2 and MMP-13 [82] . They planned to insert a long substituent into P1' to achieve selectivity over MMP-1 and synthesized compound 5-1 (Table 2) , that showed nanomolar activity on MMP-2 and MMP-13, sparing MMP-1. X-ray crystallography revealed that the sulfonyl group of the inhibitor made a single hydrogen bond with Leu160 and that the piperidine-O-phenyl moiety extended into the S1' subsite making van der Waals contact with the protein.
A series of papers describing novel anthranilic acid scaffold-based MMPIs (6) ( Table 2 ) has been recently published by Levin et al. at Wyeth-Ayerst [83] [84] [85] . Structure-activityrelationship (SAR) for variation of the 3-, 5-positions and P1 moiety led to the lead compounds with nanomolar level in vitro activity against various MMPs. Among these sulfonamide derivatives, the 4-pyridyl ether 6-1 ( Table 2) , a potent MMP-9 and MMP-13 inhibitor, displayed the highest selectivity over MMP-1, due to the length of the P1' alkoxy moiety. This compound also demonstrated oral activity in a rat sponge-wrapped cartilage model.
A series of succinyl hydroxamic acids as potent and selective inhibitors of MMP-3 was discovered as reported by Fray et al. at Pfizer, UK [68, 86] . It was discovered that inhibitory potency against MMP-1 could be dramatically reduced by subtle modifications to P3 group. Compound (7-1), UK-356,618 ( Table 2) , was the most potent and selective MMP-3 inhibitor reported at that time.
Since inhibition of MMP-1 may be responsible for the musculoskeletal side effects observed clinically with broadspectrum inhibitors, Pikul et al. were especially interested in molecules that would spare this enzyme [66] , they believed that an additional ring substituent capable of interacting with the S2 binding site could provide an opportunity to modify not only the potency but also the selectivity of such inhibitors against various MMPs. Modification of the P2 substituent could provide such selectivity due to the hydrophilic nature of the S2 site of MMP-1 containing Ser-222 as compared to the hydrophobic nature of their target enzymes: MMP-3 and MMP-13, which contain Leu-222 and Ile-222, respectively. Similar effects were expected for MMP-7, which has a hydrophilic threonine in the 222 position. In an effort to provide a heterocyclic template capable of additional P2 binding interactions, they designed a new series of MMPIs based on a scaffold containing a central ring of sixmember hexahydropyrimidines. Compound 8-1 ( Table 2) containing a tert-butyl P2 group was found to have 1 nM potency for MMP-2, -3, -8, -9, and subnanomolar potency for MMP-13.
Baxter et al. at Celltech disclosed novel arylsulfonyl hydroxamic acids (9) ( Table 2 ) as potent and selective MMP inhibitors through computer-aided molecular design (CAMD) techniques [87] . The lead compound (9-1) ( Table  2 ) exhibited excellent inhibitory potency against MMP-2, MMP-3, MMP-8 and MMP-9, and a superior selectivity profile over MMP-1, and displayed significantly better inhibition in in vivo models of arthritis and cancer. The predicted binding mode in MMP-8 put the arylketone moiety of 9-1 in the S1 pocket. In MMP-1, this substituent was predicted to bind along the prime side substrate binding groove and not in the S1 pocket.
Recently, a series of -amino--sulphone hydroxamic acids (10) ( Table 2 ) was discovered as potent inhibitors of MMP-13 that spare MMP-1 [88] . Potency and selectivity could be modulated by varying the P1 moiety. Compound (10-1) ( Table 2 ) also showed good absorption when administered orally to the rat. The same group disclosed thatalkylated derivatives, such as (11-1), showed highly potent inhibitory activity against MMP-2 and MMP-13 [89] .
Levin et al. thought that the oral activity could be greatly enhanced by the incorporation of a basic amine moiety into the inhibitor molecule. So they reported the synthesis and evaluation of a series of anthranilate hydroxamates 12 ( Table  2) , containing basic amine groups at R 2 or R 3 [85] . Compound 12-1 ( Table 2 ) was potent inhibitor of MMP-9 and MMP-13 in vitro. A single crystal X-ray structure of 12-1 bound to the active site of MMP-13 showed that the anthranilate phenyl ring lied near the S2' subsite, the biaryl ether was buried in the S1' pocket and the piperazine ring was solvent exposed. The potency of 12-1 versus MMP-1, despite its lengthy P1' group, was consistent with previous data from this series [84] and indicated that the arginine residue that formed the bottom of the MMP-1 S1' pocket was pushed aside to some degree by the P1' substituent, extending the depth of the pocket.
Nelson et al. have recently published an interesting study on a series of cyclic sulfonamidic hydroxamates 13 ( Table  2) , designed using a benzodiazepine template as a framework [90] . In order to provide compounds with improved selectivity for MMP-13 they introduced bulky substituents in the aryl sulfonic portion. Compound 13-1 ( Table 2) , again with the 4-pyridyl ether in P1', displayed a 381-fold selectivity for MMP-13 over MMP-1.
Succinylhydroxamates selective for MMP-2 over MMP-3 have been obtained by Marcq et al. [91] . They planned to increase the selectivity by increasing the overall hydrophobicity of the new compounds 14 ( Table 2) . Hence, an insaturation in P1' was introduced, together with an alkylic substituent in the P2' indole ring. The new derivatives were tested in vitro on MMP-2 and MMP-3 and compound 14-1 ( Table 2) , with an isobutylidene group of E geometry in P1', showed a 100-fold greater selectivity for MMP-2 over MMP-3. Potency and selectivity depended on the double bond geometry since the equimolar E/Z mixture displayed lower inhibitory potency than 14-1. The substituted indole derivative showed lower inhibitory activities, but a selectivity for MMP-2 was still observed.
Starting from the hypothesis that in many classes of peptide-mimic enzyme inhibitors, even small structural modifications may significantly influence their potency and/or selectivity, Rossello et al. planned the synthesis of new arylsulfonamido compounds [92] , taking as a structural model CGS 27023A, 2, The N-biphenylsulfonyl-N-isopropoxyaminoacetohydroxamic acid 15-1 ( Table 2 ) was synthesized and showed a good potency and selective activity on MMP-2.
In the search for new templates that may offer different selectivity profiles, sultam hydroxamates 16 ( Table 2) have been proposed as novel MMPIs by Cherney et al. [93] . Compound 16-1 ( Table 2 ) was found to be potent and selective for MMP-2, MMP-9 and MMP-13 over MMP-1. The crystal structure of 16-1 complexed with MMP-13 indicated that the pro-(S) sultam sulfonyl was able to form a hydrogen bond with Leu 185 and that the N-methylene of the sultam gave the biaryl the critical turn necessary to align the biaryls into the S1' pocket. Initial pharmacokinetic assays suggested that the sultam hydroxamates were orally bioavailable.
In an aim to improve the potency of some molecules towards MMP-2 and MMP-9, and also towards MMP-14, Rossello et al. developed some new N-i-propoxy-Nbiphenylsulfonylaminobutylhydroxamic acids in the class of MMPIs [94] . In these new type hydroxamates 17 ( Table 2) , they have introduced some alkyl substituents possessing an increasing steric bulkiness and lipophilicity in R 2 , this new R 2 substitution site strongly favoured lipophilic interactions with the nearby S1 region of the enzyme site, reinforcing the binding of the planned new inhibitors to the active site of MMP-2 and MMP-14. In consideration of the differences existing in the S1, S1 and S2 pockets between MMP-1, MMP-2 and MMP-14, the combination of appropriate molecular geometries, hindrances and lipophilic characteristics of the groups R, R 1 and R 2 , introduced into type 17 compounds was useful to improve their MMPI potency and selectivity [57] . Furthermore, the new compound (R)-17-1 ( Table 2 ) might be able to give an antiangiogenic activity, seeing that they act as potent inhibitors versus MMP-2 and MMP-14, the two MMPs over-expressed in tumors characterised by particular aggressiveness, sparing the inhibitory activity on MMP-1 responsible for undesirable serious side effects.
Retrohydroxamic acid-based MMPIs
In the efforts directed toward the development of selective MMP-2 and MMP-9 inhibitors as potential antitumor agents, Wada et al. disclosed a novel series of sulfone Nformylhydroxylamine (retrohydroxamic acid) [95] . The lead series was highly selective for inhibition of MMP-2 and MMP-9 over MMP-1. Optimization of the substituent adjacent to the retrohydroxamate center led to the discovery of ABT-518, (18-1) ( Table 3) , which exhibits significant inhibition of tumor growth in animal models and is currently undergoing Phase I clinical trials in cancer patients.
Carboxylic Acid-Based MMPIs
Inhibitors containing carboxylic acid ZBGs have been the most commonly studied group after the hydroxamic acidbased MMPIs. The most apparent reason for the use of carboxylic acids as ZBGs is because these compounds are the synthetic precursors to hydroxamic acid-based MMPIs [6] . If a hydroxamic acid-based MMPI has been synthesized and tested against MMPs, often information about the carboxylic acid precursor can also be found. Detailed examination suggests that these ZBGs are coordinated in a monodentate fashion to the catalytic zinc (II) ion, so most carboxylic acidbased MMPIs (with few exceptions) have lower inhibitory activity than their bidentate hydroxamic acid analogues.
Tamura et al. examined the SAR of the amino acid residue and the sulfonamide moiety of (R)-N-sulfonylamino acid derivatives [96] . A series of aryl sulfonamide derivatives containing tetrazole and amide were found to be potent and highly selective inhibitors of MMP-9 and MMP-2. In addition, selected carboxylic acid inhibitors 19-1 ( Table 4) was orally active in animal models of tumor growth and metastasis. These results revealed the potential of N-sulfonylamino A research group at ex-Parke-Davis (now Pfizer) reported a series of biphenylsulfonamide derivatives, such as a carboxylic analogue (20-1) (PD 166793) ( Table 4) , as selective inhibitors against MMP-2, MMP-3 and MMP-13 and micromolar potency vs. MMP-1, MMP-7 and MMP-9 [97, 98] . Surprisingly, the corresponding hydroxamic acid derivative of [(S)-configuration at the -position] significantly decreased activity in vitro, and it was claimed that compound (20-1) displayed the best pharmacokinetics among this series.
In 2001, Pikul et al. explored a novel series of carboxylic acids containing a substituted piperidine [99] as represented by 21 ( Table 4) . The backbone was flexible enough for the carboxylic group to effectively complex with the catalytic zinc, yet the compound possessed the desired conformational stability due to the presence of a ring at the position to the carboxylic acid. This compound was also projected to have favorable binding interactions in the S pocket of MMP-3. It was very gratifying to see the inhibitory potency of (R)-21-1 ( Table 4 ) fall below 10 nM against MMPs -2, -8, -9, and -13, and below 100 nM against MMP-3.
Zhang et al. disclosed a novel family of carboxylic acidbased -sulfone inhibitors 22 ( Table 4 ) with excellent enzyme potency and good selectivity over MMP-1 [100] . The SAR of both P 1 and P1/P2 has shown that a straight, hydrophobic P 1 group with the optimal length was preferred and an amido-or imido-type group was critical for MMP-9 inhibitory activity. The binding mode of compound 22-1 (Table 4) was proposed based on docking the molecule into a homology model of MMP-9. The modeling indicated that a linear biaryl acetylenyl group well fited into the S 1 pocket and the -sulfonyl function formed a hydrogen bond interaction with Ala 189. The phthalimido side chain was located between the S 1 and S 2 pockets, and one of the carbonyls might form a hydrogen bond interaction with Ala 191. This could rationalize that an amide or imide side chain is critical for the maintenance of the activity. The carboxylic acid series exhibited enhanced PK properties in rats compared to its hydroxamate analog. As expected, 22-1 showed high selectivity over MMP-1, which had a shallow S 1 subsite, and moderate selectivity for MMP-9 vs. MMP-3 (20-to 50-fold). The compound 22-1 was also a potent MMP-13 inhibitor.
Phosphorous-Based MMPIs
The discovery that a phosphorous-based compound could inhibit the zinc protease thermolysin prompted efforts to synthesize phosphorous-based MMPIs [101] . Despite initial excitement, phosphorous-based MMPIs have not shown inhibitory activity comparable to that of hydroxamates. Phosphorous-based inhibitors utilize either phosphonic acid or phosphinic acid groups to bind to the active site zinc (II) ion.
Recent studies demonstrated that MMP-11, overexpressed in breast cancer, was more involved in tumor formation than in tumor growth [84] . With the aim of obtaining selective MMP-11 inhibitors, Matziari et al. [102] synthesized a series of phosphinic pseudopeptides bearing long P1' side chains, since this enzyme was known to have a very deep S1' cavity. These researchers found that compounds containing groups at the ortho-position of the phenyl ring in P1' (such as compound 23-1) ( Table 5 ) resulted selective for MMP-11, with two orders of magnitude potency lower over the other deep pocket MMPs. This unusual selectivity could be due to the interaction of the ortho groups with MMP residues located at the entrance of the S1' cavity. These results suggest that the development of compounds able to probe the entrance of the S1' cavity, instead of its bottom part, might represent an alternative strategy to gain selectivity, also because the upper segment of S1' loop displays high sequence variability among the different MMPs.
Biasone et al. devised and evaluated a stereoselective and straightforward method [103] of synthesis of (R)--biphenylsulfonylamino-2-methylpropyl phosphonates 24 ( Table 5) . Screening of the new compound (R)-24-1 ( Table  5) on MMP-1, -2, -3, -7, -8, -9, -13 and -14 showed IC 50 in the range of nM in most cases.
Previously, Breuer et al. have reported the MMPI activity of series of alkyl-and cycloalkylcarbamoylphosphonates [104, 105] and, in more depth, the in vivo antimetastatic and antiangiogenic activity of cyclopentylcarbamoylphosphonic acid [106] . Parallel, they have found that introduction of amino groups into alkylcarbamoylphosphonates enhances their zinc binding and MMP inhibiting potency [107] . Therefore, through combining the two structural features, (a) an alicyclic ring and (b) an amino group, into one molecule, they synthesized aminocycloalkylcarbamoylphosphonates to examine their biological characteristics [108] , and revealed that only the cis-isomer 25-1 ( Table 5 ) had significant biological activity relevant to the metastatic process. It reduced metastasis formation in mice by ~90% when administered by a repetitive once daily dosing regimen of 50 mg/kg via oral or intraperitoneal routes and was nontoxic up to 500 mg/kg, following intraperitoneal administration daily for two weeks. 
Thiol-Based MMPIs
MMPIs that utilize thiol ZBGs have been synthesized and demonstrate, in some cases, inhibition at sub-nanomolar concentrations [109] [110] [111] [112] [113] . Thiol-based MMPIs have been of interest due to the apparent thiophilicity of the zinc (II) ion in a number of proteins. Zinc is found coordinated by Cys residues in many proteins including 'zinc fingers', liver alcohol dehydrogenase (LADH), and metallothioneins [114] . Greater interest in thiol ZBGs was sparked from the discovery of the 'cysteine switch' self-inhibitory mechanism of MMPs (vide supra) [115] .
Since sulfides are known to be good ZBGs for MMPs, pyridylthiol-based MMPIs (26) ( Table 6 ) were synthesized and tested [116] . As a result, compound 26-1 ( Table 6) showed better inhibition for MMP-2 and MMP-9 over MMP-1. This compound is advantageous as it is small and readily accessible in one synthetic step from commercially available materials.
Mercaptosulphide inhibitors that have been developed and characterized for several MMPs exhibit IC 50 and K i values comparable with those of well-known hydroxamic acids [117] [118] [119] . Novel and potent MMP inhibitors 27 ( Table 6 ) with a mercaptosulphide zinc-binding functionality have been designed, synthesized, and tested against human MMP-14 along with other MMPs [120] . One of the most potent inhibitors tested, YHJ-224 (27-1), showed selective inhibition for MMP-14. These results provide a model for mercaptosulphide inhibitor binding to MMP-14 that may aid in the design of more potent and selective inhibitors for MMP-14.
Thiirane-Based MMPIs
Brown et al. recently reported the design and in vitro evaluation of racemic 2-(4-phenoxyphenylsulfonylmethyl) thiirane (compound 28) ( Table 7 ) [121] . This compound was a potent and selective inhibitor for human gelatinases. In order to study if one or both of the enantiomers would exhibit the biological activity, they reported the facile synthe- ses of optically active (R)-and (S)-enantiomers of compound 28 [122] , and found that they were equally active in inhibition of gelatinases.
Another strategy followed to achieve selective MMPIs was the development of mechanism-based thiirane inhibitors. Bernardo et al. [123] reported the synthesis and kinetic characterization of slow-binding inhibitors that covalently bind to the MMP active site. These inhibitors resulted selective for MMP-2, MMP-9 and successively were improved to obtain compound 29 ( Table 7 ) [124] which proved to be selective only for MMP-2. In these thiirane-containing inhibitors the sulfur first coordinates with the catalytic zinc ion and then this interaction activates the thiirane for nucleophilic attack by the active site glutamate (Glu404 in MMP-2), a process that covalently modifies the enzyme causing a loss of activity. These inhibitors are the first example of suicideinhibitors of MMPs.
Other MMPIs
Recently, 5-substituted-1,3,4-thiadozole-2-thione compounds have been reported that contain a novel ZBG where coordination occurs through the exocyclic sulfur of a thiadiazole group [125] . SAR studies have shown that thiadiazoles are selective for MMP-3 over MMP-2 with little or no affinity for MMP-1. MMP-3, in particular, has been shown to promote mammary carcinogenesis in mice [126] . MMP-3 inhibition was further improved using a pentafluorophenylalanine substituent which resulted in 30-1 ( Table 8) derived from a 6H-1,3,4-thiadiazine scaffold [127] .In contrast to the established MMPIs, which exclusively bind to the primed side, the compounds described interact with both the primed and the unprimed side of the MMP. Further optimization of the lead compounds revealed general design principles that involve the placement of a phenyl or thienyl group at position 5 of the thiadiazine ring, to improve unprimed side affinity; the incorporation of an amino group at position 2 of the thiadiazine ring as the chelating agent for the catalytic zinc; the placement of a N-sulfonamide-substituted amino acid residue at the amino group, to improve primed side affinity; and the attachment of diverse functional groups at position 4 or 5 of the phenyl or thienyl group at the unprimed side, to improve selectivity. The new compounds were assayed against seven different matrix metalloproteinases, MMP-1, MMP-2, MMP-8, MMP-9, MMP-12, MMP-13 and MMP-14 respectively. A unique combination of the above-described modifications produced the selective inhibitor 31-1 with high affinity for MMP-9 (Ki=40 nM). This compound may be regarded as a novel, nonpeptidic, and low molecular weight lead for continued development of MMP inhibitors as drugs. (Table 8 ) as a new class of MMPIs [128] . Modeling work with the pyrimidine-2,4,6-trione suggested that the phenyl group at C-5 would fit into the S1 pocket and that since this pocket is a very deep cleft, the phenyl with a longer aromatic unit should improve potency. So the 4-phenoxyphenyl derivative 32-1 ( Table 8 ) was prepared, and showed much more inhibitory activity against both MMP-2 and MMP-9. While of the barbiturate structural class, compound 32-1 did not show any toxic or sedative effects.
Simultaneity, Grams et al. identified the pyrimidinetrione template as an efficient zinc-chelating moiety. By using structure-based drug design and combinatorial chemistry, they developed pyrimidine-2,4,6-trione derivatives with a high selectivity toward MMP-2, MMP-9, and MMP-14 [129] , such as Ro-28-2653 (33-1) ( Table 8) . These three MMPs are most consistently detected in malignant tissues and are associated with tumor aggressiveness, metastatic potential, and a poor prognosis [130, 131] . This inhibitor with high selectivity for MMP-2, MMP-9 and MMP-14, showed a good anti-invasive activity in a chemoinvasion assay and in vivo reduced the growth of tumors induced by inoculation of cell lines producing MMPs. Moreover it reduced tumor vascularization and blocked angiogenesis in a rat aortic ring assay [132] .
A further example of new non-hydroxamate ZBG has been proposed by Augé et al. [133] , who inserted new chelating portions on the Galardin scaffold. The most promising ligands 34 ( Table 8 ) resulted to be those containing a hydrazide moiety, since compound 34-1 ( Table 8 ) of this class showed a high activity (IC 50 = 30 nM) and selectivity for MMP-2 over MMP-1. This derivative presented a sulfonylhydrazide group responsible for the increased acidity of the N-H, close to the SO 2 group, which enhances H-bonding to the glutamate residue in the active site. Such substitution also increases the partial negative charge on this nitrogen, strengthening the bonding to the zinc ion.
Recently, a new original approach to MMP-9 selectivity was described by Banerjee et al. [134] who synthesized differently branched benzenesulfonamide derivatives 35 ( Table  8 ) able to block the accessibility of the enzyme's active site without fitting into the active site pockets. The inhibitors contained short chain spacers that terminated into iminodiacetate IDA-Cu 2+ moieties preferentially interacting with the imidazole group of the histidine residues exposed on the enzyme surface. In particular, the number of surface histidine residues is higher in MMP-9 than in other MMPs, so compound 35-1 ( Table 8) showed a good selectivity for this enzyme. These "multi-prong" conjugates represent a first example of this kind of inhibitor, whose potency can be significantly increased.
As histidine imidazoles serve as ligands for the catalytic zinc in the active site of MMPs, this heterocycle should be ideal for binding the catalytic Zn. Ryuji et al. envisioned the readily accessible triazole to be similar. Oxazoline heterocycles are also well known as ligands for Lewis acids [135] and they have previously utilized them for MMP inhibition [136] . So Ryuji et al. hypothesized the combination of oxazoline and triazole would be useful for chelating to Zn (II) [116] . Thus, oxazolinyl triazole compounds were prepared and found that only the cinnamyl derivative (36-1) ( Table 8) showed any activity at all with modest inhibition of MMP-2 and slightly improved inhibition of MMP-12. They also synthesized and tested tetrazole templates as well. Since it has been shown that bidentate ligands have much better inhibitory potency than monodentate ligands, an additional potentially chelating heterocycle was incorporated into the design. Interestingly, compound 37-1 ( Table 8) , which possesses a long flexible substituent, showed selective inhibition for MMP-2 (32 M). So they next investigated MMPIs with potentially larger sixmembered ring chelation. Interestingly the unsubstituted pyridylmethyl tetrazole 38-1 ( Table 8 ) afforded complete selectivity for MMP-2 with a good level of inhibition.
Natural Products
The primary focus of this section will be the numerous attempts that have been made to find, or develop, MMPIs that may be derived from natural resources such as herbs, plants, fruits, and other agriculture products. New and potentially beneficial compounds isolated from these sources have been shown to exhibit some degree of MMPI activities, but they are far less potent and specific than the TIMP family. These natural compounds include long chain fatty acids, polyphenols, flavonoids, and a variety of other natural compounds
Long Chain Fatty Acids
Long-chain fatty acids inhibit MMP-2 and MMP-9 with Ki values in the micromolar range [137] , although they demonstrated weak inhibitory effects against MMP-1. The fatty acid chain length and its degree of saturation is related to the level of inhibition, as C18 fatty acid showed stronger inhibition than C16, C14, and C10, and the degree of nonsaturation was shown to correspond to and enhance the overall inhibitory capacity of the chains [137] . Experiments with human skin tissue sections revealed that micromolar concentrations of elaidic acid (39) (Fig. 7) , a long-chain unsaturated fatty acid, protected collagen and elastin fibers against degradation by MMP-2 and MMP-9 respectively [137] .
Long-chain unsaturated fatty acids have also been reported to inhibit both the expression and activity of a member of a different metalloproteinase family, aggrecanases [137, 138] . Oleic acid (40) (Fig. 7) , an 18-carbon fatty acid with one double carbon bond in the cis position, inhibited hydrolysis of a fluorogenic peptide substrate by MMP-2 in a dose dependent manner [137, 139, 140] . Sodium 1-(12-hydroxy)-octadecanyl sulfate (41) (Fig. 7) , which was isolated from a marine tunicate as a 55:45 mixture of 12R and 12S isomers [141] , inhibited MMP-2 with an IC 50 value of 9.0 g/mL.
Fujita et al. reported Callysponginol Sulfate A (42) (Fig.  7) , a new sulfated C24 acetylenic fatty acid isolated from the Marine Sponge Callyspongia truncate, as a MMP-14 inhibitor [142] . This compound inhibited recombinant MMP-14 with an IC 50 of 15.0 mg/mL
Polyphenols and Flavonoids
Polyphenols and flavonoids down-regulate the expression of MMPs in different cell types, inhibiting cancer cell invasion. The reactive oxygen species generated by oxidative stress can induce the expression of MMPs, and because polyphenols and flavonoids are well known antioxidants and radical scavengers, the down-regulation of MMPs by these compounds may be the result of their ability to interfere with the pathways of oxidative stress response. Their inhibition of MMPs at the levels of expression and enzymatic activity suggest that polyphenols and flavonoids might also influence the processes of extracellular matrix degradation and remodeling, which may in turn contribute to the antimetastatic and antiarteriosclerotic effects of these compounds.
Epigallocatechin gallate (EGCG) (43) (Fig. 8) , a polyphenol catechin isolated from green tea, has been drawn great attention over the past few years for its therapeutic potential in numerous diseases. EGCG can act as a potent MMPI [143] targeting multiple MMP-mediated cellular events in cancer cells, thereby providing a new mechanism for the anticancer properties of this molecule in human prostate carcinoma DU145 cells, the inhibition of MMP-2 and MMP-9 by EGCG is mediated via inhibition of phosphorylation of ERK1/2 and p38, and inhibition of activation of the transcription factors c-jun and NF-kB [144] . EGCG repressed the invasion of lung carcinoma 95-D cells in invasion assays [145] , and reverse transcriptase polymerase chain reaction (RT-PCR) analyses showed that EGCG downregulated the expression of MMP-9 [145] . EGCG has a potent and distinct inhibitory activity against MMP-14 [146] . In U-87 glioblastoma cells, the addition of EGCG strongly inhibited MMP-14-dependent proMMP-2 activation [147] . The inhibitory effects of EGCG on MMP-14 were also demonstrated by the down-regulation of MMP-14 transcript levels, and by the inhibition of cell migration by MMP-14 transfected COS-7 cells, suggesting that this catechin may act at both the gene expression and protein activity levels [147] .
Two biphenol compounds, Magnolol 44 and Honokiol 45 ( Fig. 8) , from Magnolia obovata bark extract, have been found to inhibit the activity of MMP-9 [148] . These compounds inhibited the migration of HT-1080 cells at a concentration of 100 mM, as well as their invasion through a Matrigel barrier [148] . 44 also exhibited significant in vivo antimetastatic effects in a murine liver and spleen metastasis model utilizing a lymphoma line, as well as a murine lung metastasis model utilizing a melanoma line [149] .
Pine bark extract has been used in Europe and North America for the treatment of wound healing and for inflammatory diseases [150, 151] , and the procyanidin-rich maritime pine bark extract pycnogenol has well-documented antioxidant and anti-inflammatory activity [151] . Two major metabolites of pycnogenol, 46 and 47 (Fig. 8) , respectively, exhibit strong inhibitory effects towards the activity of MMP-1, MMP-2, and MMP-9, and both metabolites appeared more active than pycnogenol [151] . It was also demonstrated that the inhibition of MMP-9 by both metabolites, but not pycnogenol, were reversed in the presence of Zn 2+ , suggesting that these metabolites might be capable of interacting with Zn 2+ and bind directly at the active site of MMP-9. In addition, both metabolites inhibit MMP-9 expression by human monocytes in a dose-dependent manner, and only sub-micromolar concentrations of both compounds were required to achieve 50% inhibition of MMP-9 secretion [151] .
Caffeic acid (CA) (48) (Fig. 8) , found in fruits, vegetables, wine, olive oil, and coffee [152] , has been shown to inhibit the activity of MMP-9 and a CA derivative, chlorogenic acid (CHA) (49) (Fig. 8) , has been isolated from the stem barks of Euonymus alatus [153] . CHA also exerts a strong inhibitory effect against MMP-9 activity in a concentration-dependent manner as determined by zymography [153] . Furthermore, one of its synthesized derivatives, caffeic acid phenethyl ester (CAPE) (50) (Fig. 8) , could selectively inhibited MMP-2 and -9 but not -1, -3, -7 [154] at the same time. Jin et al. [155] Fig. (7) . Representative of long chain acids. selective inhibitor of MMP-9 from propolis, confirmed the cross-inhibitory effect of CAPE on MMP-9 by the artificial substrate and gelatin zymography. CAPE dramatically inhibits MMP-9 enzyme activity in a dose-dependent manner, understanding the molecular mechanisms by which CAPE interact with and inhibit these enzymatic activities, thus restraining matrix degradation and cell invasion, is therefore important in exploiting its properties for cancer prevention and treatment, and will serve as a basis for designing even more effective anti-invasion drugs.
Ipomoea pes-caprae is used in some parts of the world to treat fatigue, strain, arthritis, and rheumatism [156] , and two new quinic acid esters (51 and 52) (Fig. 8) isolated from this herb have been shown to possess collagenase inhibitory activities [156] .
Resveratrol (53) (Fig. 8) , a naturally occurring compound present in grapes and other plants, provides cancer chemopreventive effects in different systems based on its striking inhibition of diverse cellular events associated with tumor initiation, promotion, and progression. Studies on proteinases demonstrated that resveratrol inhibited the secretion of MMP-2 [157] . Treatment of HUVECs for 24 h with resveratrol caused a dose-dependent reduction of the secreted 72 kDa MMP-2 gelatinolytic activity in the conditioned medium. Densitometric analysis showed that 40 mol/L resveratrol caused a 35% decrease in MMP-2. No gelatinolytic activity corresponding to MMP-9 was detectable in the conditioned medium of HUVECs.
Investigation of collagenase inhibitory natural components afforded two quinic acid esters (54 and 55) (Fig. 8) from the leaves of Pluchea indica (Compositae) [158] , compounds 54 and 55 exhibited collagenase inhibitory activity (IC 50 ) at a concentration of less than 10 M. Furthermore, 54 showed MMP-2 and MMP-9 inhibitory activity (IC 50 ) at 2.5 and 6.4 M respectively.
Flavonoids have also been found to have inhibitory activities toward MMPs. Ende et al. tested 8 flavonoids (56-63) (Fig. 8) including primuletin, chrysin, apigenin, kaempferol, luteolin, luteolin-7-O-glucosid, diosmetin, quercetin for their inhibitory effects on the recombinant catalytic domains of MMP-2 and -9, and found that these flavonoids inhibit MMP-2 and MMP-9 in the micromolar range [159] . Kinetic analyses using luteolin revealed that this inhibition is noncompetitive [159] .
Other Natural Compounds
Other natural products found to inhibit MMPs include futoenone (64) and its derivative (65) (Fig. 9) . Futoenone is found in the Chinese herbal plant Piper futokadsura, which is used to treat inflammatory disease [70] . 64 and 65 have been studied as MMPIs and demonstrate modest inhibitory activity [70] . The mode of binding of these compounds to MMPs is unknown, however, it is proposed that the 2-methoxyphenol moiety in these molecules is responsible for zinc chelation [70, 160] .
The tetracycline antibiotic, periostat (66) (Fig. 9) , is used as an MMPI to treat periodontal disease [161] . Despite modest in vitro inhibition of MMPs, tetracyclines have shown promising anti-tumor potential [162, 163] . The origin of their anti-tumor activity is unclear as tetracyclines can interact with multiple targets in vivo, and may inhibit MMPs directly or by preventing the synthesis or activation of MMPs [164] .
In the search for new anticancer agents, chemically modified tetracycline (CMT) [165] was designed to inhibit MMP activity and thus reducing the spread of tumor cells. The first series of CMT was obtained by removing the dimethylamino group from the carbon-4 position. The resulting compound 67 ( Fig. 9) was devoid of any antimicrobial activity but presented anticollagenolytic activity both in vitro and in vivo. Based on this finding, other modifications were made to the tetracycline scaffold and eight analogues were synthesized. Preclinical studies demonstrated that CMT can inhibit gelatinases, stromelysins, collagenases and MT-MMPs. MMP inhibition could be due to chelation of the Zn site, resulting in disruption of the normal conformation of the protein. Besides CMT down-regulated the expression of gelatinases, thus reducing the production of pro-enzymes, and inhibited the activation of pro-gelatinases and procollagenases. COL-3 (68) (Fig. 9) is one of the first developed CMTs that has shown specificity towards MMP-2, MMP-9 and MMP-14. There is evidence that COL-3 has an inhibitory effect on MMPs by decreasing trypsinogen-2 and inducible nitric oxide (iNO) production, which are known to be regulators of MMP activity. In fact trypsinogen-2 plays a significant role in activation of pro-MMPs and therefore in invasiveness of tumor cells. COL-3 is currently being evaluated in clinical phase II trials but, unfortunately, it showed an extremely poor solubility and stability profile. Unacceptably high incidences of photosensitivity skin reactions were noted together with nausea and leukopenia [166] . Studies are underway to identify analogues of COL-3 with better pharmacokinetic properties, since CMTs have promising antiproliferative and anti-metastatic activity.
Fujita et al. have reported that ageladine A (69) (Fig. 9) , a fluorescent alkaloid isolated from the marine sponge Agelas nakamurai, inhibits MMP-1, -8, -9, -12, and -13 with IC 50 values of 1.2, 0.39, 0.79, 0.33, and 0.47 mg/mL respectively [167] . This compound could also inhibit MMP-2 with an IC 50 of 2.0 mg/mL, but N-methylated derivatives did not inhibit MMP-2. The inhibition is not due to Zn 2+ chelation, as ageladine A is not capable of chelating to Zn
2+
, and a kinetic analysis indicated that the inhibition was not competitive. In addition, bovine aortic endothelial cell migration and vascular formation by murine ES cells were significantly inhibited by this compound.
Bao et al. found that 1,25-VD (70) (Fig. 9) decreased MMP-9 and cathepsins (CPs), while it increased the activity of their counterparts, TIMP-1 and cathepsin inhibitors. Mechanistic studies showed that 1,25-VD did not suppress MMP-9 expression at the transcriptional level, but reduced its mRNA stability. In addition, 1,25-VD increased AP-1 complexes binding to TIMP-1 promoter, which contributed to the enhancement of TIMP-1 activity, and thus resulted in inhibition of MMP activity and tumor invasion. These findings support the idea that vitamin D-based therapies might be beneficial in the management of advanced prostate cancer, especially among patients who have higher MMP-9 and CPs activities [168] .
Recently, gelastatins (71) (Fig. 9) were isolated from the culture broth of Westerdykella multispora as a mixture of olefinic isomers [169] . Gelastatins (71) (Fig. 9) and its hydroxamates (72) (Fig. 9) were evaluated on various in vitro assays [170] . 71 showed good inhibitory activity against only MMP-2 and moderate inhibitory activity against MMP-9, on which their IC 50 were 630, and 5290 nM respectively. However, 72 showed very potent enzyme inhibitory activities against MMP-2 and MMP-9, on which their IC 50 were 6 and 23 nM respectively.
In order to search for new natural inhibitors against MMP-9, Zeng et al. performed the inhibition assays of MMP-9 on 96-well microtiter plates [171] . With random screening, results indicated that 73 (Fig. 9) , which was isolated from Winchia calophylla, could inhibite MMP-9 with IC 50 was 7.95 g/ml. The other natural product 74 (Fig. 9) , which was isolated from Illicium simonsii, could inhibite MMP-9 with IC 50 was 5.80 g/mL.
CLINICAL TRIALS
Batimastat was the first MMP inhibitor entered into clinical trials for treatment of cancer [172] . In phase I studies, it was given to patients with malignant ascites as well as malignant pleural effusion via direct instillation into the peritoneal and pleural cavities. Batimastat was well tolerated, but short-lasting mild abdominal pain associated with nausea and vomiting was noted in about half of the patients. Further development of this compound has been suspended.
Marimastat proved to be efficient in phase III toward pancreas cancer, but failed in breast or lung cancer. Severe musculoskeletal pain was noted in 18% of patients treated with marimastat, and quality of life was significantly worse in this group of patients [173] .
CGS 27023A has been stopped in clinical trials in 2001 [174] , as arthralgia and/or myalgia in the upper limbs was observed in 40% of patients treated at all dose levels with the onset several weeks after the start of treatment with CGS 27023A. The frequency and severity of arthralgia and myalgia did not appear to be dose related and symptoms settled over time after stopping the drug.
The halofunginone was initially designed as an antiparasitic drug which, however, proved to be an effective MMPI despite the lack of obvious ZBG in its structure. The antitumoral effect was associated with decreased tumor angiogenesis rather than a direct cytostatic effect on the tumor cells. Some studies show that halofuginone therapy shows promise for hitherto medically untreatable von HippelLindau (VHL)-associated disease [175] .
BMS-275291 was a selective MMPI that did not inhibit sheddases implicated in the dose-limiting arthritis of older MMPIs. It was well tolerated in hormone-refractory prostate cancer (HRPC) patients and had no dose-limiting arthritis. So it was recommended for future studies [176] .
Biphosphonates which are useful drugs in osteoporosis treatment of menopaused women have been shown to inhibit tumor cell adhesion, invasion, and proliferation, and they induce apoptosis of a variety of human tumor cell lines in vitro [177] . Two larger phase III trials of bisphosphonates as adjuvant therapy for primary breast cancer, each enrolling more than 3000 patients with early-stage breast cancer, are underway. It was anticipated that the use of dose-dense bisphosphonate therapy as adjuvant treatment of primary breast cancer will decrease the risk of bone metastases [178] .
Finally, despite the large number of active derivatives assayed in vitro or in animal experimental models, there are only two drugs launched on the market: Periostat (doxycycline) [179] , a tetracycline used for periodontal disease and glucosemine sulfate [180] , for osteoarthritis. Thus, it can be reasonably stated that, today, the efficiency of MMPIs in metastatic dissemination cannot be clinically ascertained. It could be due to the way by which the clinical trials are actually performed [181] . The regulations impose that they are performed on patients with terminal-phase cancers, a situation that obviously does not correspond to the purpose of an MMPI therapy, which needs to target mainly the early phase of the cancer dissemination.
CONCLUSION
The quest for selective MMP inhibitors still constitutes one of the main challenges in the search for successful clinical candidates. Three-dimensional structures of MMP inhibitor complexes and inhibition profiles of compounds screened on MMPs provide an invaluable source to gain insight into the structural determinants of selectivity. Analysis of these data enables one to identify and characterize selectivity regions for discrimination of MMP family members. Then, one could use structure-based design techniques to identify and prioritize fragments binding to these selectivity regions. Once these fragments have been selected, structure-based design techniques could be applied to identify linkers connecting these fragments to the core of known MMP inhibitors. Application of high throughput screening has also resulted in the discovery of highly selective inhibitors. The availability of crystallographic structures of these highly selective inhibitors bound to their target has helped to optimize their potency while maintaining their selectivity. These highly selective inhibitors exploit differences in the intrinsic flexibility of the catalytic domain to form selective interactions with a given MMP. A systematic analysis of the flexibility of the different MMPs, using molecular dynamic, might contribute to identifying unique conformational features for a given MMP. These unique features might subsequently be exploited to design highly selective inhibitors for that particular MMP. These highly selective inhibitors can be utilized as a pharmacological tool to probe the effect of blocking a given MMP, while sparing the other members of the MMP family. In addition, imaging "in vivo" technologies must be developed in order to follow the drug distribution to the targeted tissues, and to quantify the drug efficiency. Overexpressed MMPs are important in at least three events in malignancy progression: (1) primary tumor growth, which requires the breakdown of the surrounding connective tissue; (2) metastasis, involving the movement of tumor cells across the vascular basement membrane; and (3) angiogenesis, the growth and entry of new blood vessels into the growing tumor. Through these methods, new hope is emerging in the form of synthetic and natural MMPIs for the prevention and treatment of cancer. tific and Technological Innovation Team for "Qinglan Project" of Jiangsu College and University. 
